Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia

This study has been completed.
Information provided by (Responsible Party):
AMAG Pharmaceuticals, Inc. Identifier:
First received: April 29, 2010
Last updated: May 29, 2013
Last verified: May 2013
To evaluate the safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia (IDA).

Condition Intervention Phase
Iron Deficiency Anemia
Drug: Ferumoxytol
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III, Open-Label Extension Trial of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia

Resource links provided by NLM:

Further study details as provided by AMAG Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Hemoglobin changes [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Patient reported outcomes [ Designated as safety issue: No ]

Enrollment: 634
Study Start Date: July 2010
Study Completion Date: May 2013
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ferumoxytol
Safety and efficacy of intravenous (IV) ferumoxytol for the treatment of iron deficiency anemia (IDA)
Drug: Ferumoxytol
IV Ferumoxytol
Other Name: Feraheme


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria include:

  1. Subjects who completed participation in study AMAG-FER-IDA-301
  2. Female subjects of childbearing potential who are sexually active must be on an effective method of birth control and agree to remain on birth control until completion of participation in the study

Key Exclusion Criteria include:

  1. Experienced a serious adverse event (SAE) related to ferumoxytol in study AMAG-FER-IDA-301
  2. Female subjects who are pregnant, intend to become pregnant, are breastfeeding, or have a positive serum/urine pregnancy test
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01114217

United States, Massachusetts
AMAG Pharmaceutcials, Inc.
Lexington, Massachusetts, United States, 02421
Sponsors and Collaborators
AMAG Pharmaceuticals, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: AMAG Pharmaceuticals, Inc. Identifier: NCT01114217     History of Changes
Other Study ID Numbers: AMAG-FER-IDA-303 
Study First Received: April 29, 2010
Last Updated: May 29, 2013
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Hungary: Ministry of Health, Social and Family Affairs
India: Central Drugs Standard Control Organization
Latvia: State Agency of Medicines
Poland: Ministry of Health

Keywords provided by AMAG Pharmaceuticals, Inc.:
Iron deficiency anemia
GI disorders
postpartum anemia
The treatment of iron deficiency anemia (IDA)

Additional relevant MeSH terms:
Deficiency Diseases
Anemia, Iron-Deficiency
Hematologic Diseases
Nutrition Disorders
Anemia, Hypochromic
Iron Metabolism Disorders
Metabolic Diseases
Ferrosoferric Oxide
Trace Elements
Growth Substances
Physiological Effects of Drugs
Parenteral Nutrition Solutions
Pharmaceutical Solutions processed this record on January 14, 2017